Popular diabetes drugs could elevate risk of heart failure and deathDecember 4th, 2009 - 4:48 pm ICT by ANI
London, Dec 4 (ANI): Sulphonylureas, a type of drug widely used to treat type 2 diabetes, has a greater risk of causing heart failure and death as compared to metformin, another popular antidiabetes drug, according to a study.
The findings suggest that clinically important differences in the cardiovascular safety profiles of different antidiabetes drugs, and support recommendations that favour metformin as first-line therapy for type 2 diabetes.
Type 2 diabetes affects more than 180 million people worldwide and is associated with at least a two-fold increased risk of death, mainly from cardiovascular disease.
Oral antidiabetes drugs are widely used to help control blood sugar levels, but there are concerns that some may increase cardiovascular risk.
Thus, researchers led by Professor Paul Elliott from Imperial College London set out to investigate the risk of heart attack (myocardial infarction), congestive heart failure and death from any cause associated with prescription of different types of oral antidiabetes drugs.
They used data from 91,521 men and women (average age 65 years) with diabetes included in the UK General Practice Research Database between 1990 and 2005 and took into account factors that could potentially affect the results.
Metformin was the most commonly prescribed drug, followed by second generation sulphonylureas.
Compared with metformin, both first and second generation sulphonylureas were linked with significant excess risk of all cause mortality, and second generation sulphonylureas with up to 30 percent excess risk of congestive heart failure.
Another class of antidiabetes drugs called thiazolidinediones were not associated with risk of heart attack, and there was significantly lower risk of all cause mortality associated with pioglitazone use compared with metformin.
“The sulphonylureas, along with metformin, have long been considered the mainstay of drug treatment for type 2 diabetes. Our findings suggest a relatively unfavourable risk profile of sulphonylureas compared with metformin,” the British Medical Journal quoted the authors as saying.
The study has been published on bmj.com. (ANI)
- Drug used to treat type 2 diabetes linked to heart problems - Mar 18, 2011
- Some diabetes drugs are better than others: Study - Apr 07, 2011
- BP drug not tied to death risk among heart patients - Apr 11, 2012
- No link between diabetes drug and rise in heart attacks - Jun 30, 2010
- Diabetes drug may elevate bladder cancer risk - Jul 04, 2012
- Diabetes drug reduces cancer risk - Nov 27, 2011
- Intense diabetes treatment could make sugar levels go 'too low' - Jan 27, 2010
- Vitamin E can fight fatty liver disease in kids - Apr 28, 2011
- Diabetes drug 'increases heart failure risk' - Aug 21, 2009
- Diabetes drug may boost power of anti-depressants - May 03, 2012
- Healthy lifestyle could help keep diabetes at bay for a decade - Nov 03, 2009
- Heart risks linked to diabetes drug - Jun 29, 2010
- Diabetes drug can raise heart disease risk by 25 percent - Mar 18, 2011
- Leaner diabetics have higher death rate - Aug 08, 2012
- Early metformin treatment doubles chance of success for diabetics - Mar 10, 2010
Tags: account factors, blood sugar levels, cardiovascular risk, cause mortality, congestive heart failure, control blood sugar, diabetes drugs, diabetes type 2, excess risk, heart attack myocardial infarction, heart failure, imperial college london, metformin, myocardial infarction, paul elliott, risk of heart attack, safety profiles, sulphonylureas, support recommendations, type 2 diabetes